Breast and cervical cancer patients' experience in Addis Ababa city, Ethiopia: a follow-up study protocol.
addis ababa, ethiopia
breast neoplasm
reported outcome measures
uterine cervical neoplasm
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
09 04 2019
09 04 2019
Historique:
entrez:
11
4
2019
pubmed:
11
4
2019
medline:
16
4
2020
Statut:
epublish
Résumé
Cancer is an emerging public health problem in Ethiopia, with breast and cervical cancers accounting for over half of all newly diagnosed cancers in women. The majority of women with breast and cervical cancer are diagnosed at late stage of the disease and most patients do not receive care consistent with global standards. However, little is known about the health-seeking behaviours, barriers to early detection and treatment, patient-reported outcomes, financial burden and survival of women with breast and cervical cancer in the country. Therefore, this study aims to document the experience of women with breast and cervical cancer from recognition of symptoms to diagnosis, treatment and survivorship/mortality in Addis Ababa city, Ethiopia. A prospective follow-up study using mixed methods (both quantitative and qualitative) will be employed. All women newly diagnosed with breast and cervical cancer from 1 January, 2017 to 30 June 2018 in Addis Ababa will be included in the study. Interviewer-administered questionnaires will be used to collect information about medical consultations after recognition of symptoms, health-seeking behaviours, treatment received, barriers to early detection and treatment, and survivorship care. In-depth interview will be conducted on purposefully selected women with breast and cervical cancer. The primary outcomes of the study are time intervals (patient and diagnostic waiting times), stage at diagnosis and survival. Multivariable analysis will be employed to determine the contributions of independent variables on the outcomes of interest. HRs with 95% CIs will be calculated for time-to-event outcomes. Qualitative data will be analysed using thematic analysis. This protocol is ethically approved by Institutional Review Board of Addis Ababa University. Verbal informed consent will be obtained from study participants. Results will be disseminated in international peer-reviewed journals and presented in relevant conferences.
Identifiants
pubmed: 30967409
pii: bmjopen-2018-027034
doi: 10.1136/bmjopen-2018-027034
pmc: PMC6500298
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e027034Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Cancer Surviv. 2011 Sep;5(3):305-14
pubmed: 21274648
Int J Womens Health. 2017 May 22;9:365-372
pubmed: 28579837
J Oncol. 2012;2012:121873
pubmed: 22956949
BMC Cancer. 2013 Jan 02;13:2
pubmed: 23282173
World J Surg Oncol. 2018 Mar 22;16(1):63
pubmed: 29566711
Oncologist. 2014 Jul;19(7):727-34
pubmed: 24951611
Breast Care (Basel). 2015 Dec;10(6):364-70
pubmed: 26989354
J Cancer Educ. 2017 Dec;32(4):901-907
pubmed: 27075197
Arch Public Health. 2015 Aug 27;73(1):39
pubmed: 26380083
J Clin Oncol. 2007 May 20;25(15):2127-32
pubmed: 17513820
J Exp Clin Cancer Res. 2008 Aug 29;27:32
pubmed: 18759983
Cancer. 2010 Feb 1;116(3):577-85
pubmed: 20029968
Cancer. 2012 Sep 15;118(18):4372-84
pubmed: 22252462
Lancet. 1999 Apr 3;353(9159):1127-31
pubmed: 10209975
Toxicol In Vitro. 2017 Feb;38:117-123
pubmed: 27737796
PLoS One. 2016 Mar 10;11(3):e0149908
pubmed: 26963098
BMC Womens Health. 2015 Sep 16;15:75
pubmed: 26376638
BMC Cancer. 2013 Feb 08;13:69
pubmed: 23391288
Cancer Epidemiol. 2018 Apr;53:93-98
pubmed: 29414637
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):444-457
pubmed: 28223433
Obstet Gynecol Int. 2016;2016:1274734
pubmed: 27867397
ISRN Oncol. 2013 Aug 06;2013:470981
pubmed: 23986873
BMC Cancer. 2014 Nov 29;14:895
pubmed: 25433805
PLoS One. 2017 Jul 25;12(7):e0181415
pubmed: 28742851
Ethiop Med J. 2015 Apr;53(2):65-74
pubmed: 26591294
Int J Breast Cancer. 2013;2013:814395
pubmed: 24298389
Oncologist. 2015 Jul;20(7):780-8
pubmed: 26032138
Gynecol Oncol Res Pract. 2015 Sep 18;2:6
pubmed: 27231566
J Oncol. 2013;2013:206367
pubmed: 23840209
Cien Saude Colet. 2015 Oct;20(10):3177-89
pubmed: 26465859
Health Qual Life Outcomes. 2009 Dec 23;7:102
pubmed: 20030832
Infect Agent Cancer. 2017 Nov 29;12:61
pubmed: 29213299
BMC Med Ethics. 2018 Nov 14;19(1):87
pubmed: 30428895
PLoS One. 2016 Sep 30;11(9):e0163136
pubmed: 27690311
Int J Gynaecol Obstet. 2009 May;105(2):107-8
pubmed: 19342051
Int J Equity Health. 2012 Dec 29;11:83
pubmed: 23273140
Br J Cancer. 2012 Mar 27;106(7):1262-7
pubmed: 22415239
Int J Cancer. 2014 Aug 1;135(3):702-9
pubmed: 24375396
Glob Public Health. 2011;6(7):719-31
pubmed: 20865612
Int J Breast Cancer. 2012;2012:908547
pubmed: 22315692
J Affect Disord. 2015 Nov 1;186:32-9
pubmed: 26226431